Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030

Liver Cancer Drug Market Growth & Trends

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights

• The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
• Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.
• Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.
• North America liver cancer drug market held a revenue share of 42.7% in 2023.

Please note The report will be delivered in 2-3 business days upon order notification.